Loading clinical trials...
Loading clinical trials...
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer
Conditions
Interventions
Cabazitaxel
Carboplatin
+2 more
Locations
8
United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
Northwestern University
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Tulane University
New Orleans, Louisiana, United States
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Start Date
October 10, 2019
Primary Completion Date
June 19, 2023
Completion Date
May 1, 2025
Last Updated
February 28, 2024
NCT06594926
NCT06257264
NCT03620786
NCT05939414
NCT05424783
NCT04693377
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions